Stem Cell Transplantation Clinical Trial
Official title:
Physiological Responses to Maximal Exercise Capacity and Muscle Strength in Survived Hematopoietic Stem Cell Transplantation Recipients
Pulmonary functions, exercise capacity and muscle strength deteriorate in survived hematopoietic stem cell transplantation (HSCT) recipients due to toxic effects of chemotherapy, radiotherapy, conditioning regimens and/or corticosteroid use before HSCT, prolonged stay of recipients in rooms with laminar airflow and strict infection control rules during process of HSCT. There are also limited numbers of studies demonstrated pulmonary function abnormalities, decreased maximal exercise capacity, respiratory and peripheral muscle weakness in recipients. Current study was planned since no study compared pulmonary functions, maximal exercise capacity, respiratory and peripheral muscle strength between recipients and healthy individuals in the literature.
Treatments of hematologic malignancies consist of chemotherapy, radiotherapy, surgery,
medical treatment, supportive care and/or hematopoietic stem cell transplantation (HSCT)
which is resulted in early or late adverse effects on body systems, tissues and organs.
Physical deconditioning is also observed in patients with hematologic malignancies because of
reasons such as neurotoxic and pulmonary toxic effects of long term these anticancer
treatments, immobilization, recommendation of resting and avoiding intense exercise,
nutrition problems, severe anemia and thrombocytopenia etc. For these reasons, normal
physical activities may not be kept on by patients which induces decreased physical
performance.
The HSCT provides longer survival with standard treatments for patients with hematological
malignancies while it increases risk of HSCT-related toxicity, complications and even
mortality. Infectious and non-infectious pulmonary complications occur in about 60% of HSCT
recipients and intensive-care unit support is also required in one-third of recipients for
these reasons. Restrictive lung disease prior to allogeneic HSCT is related to early
respiratory failure, non-relapse mortality and respiratory muscle weakness in post
transplantation period. Therefore pulmonary restriction is considered as a risk factor for
complications or failure of HSCT. Moreover it is known that carbon monoxide diffusing
capacity of lungs which is the most common abnormality seen in pulmonary function test,
respiratory muscle strength and functional exercise capacity are reduced in the majority of
patients before HSCT. In addition to muscle weakness and decreased exercise capacity at prior
to HSCT, patients experience more reduction in both inspiratory and expiratory muscles and
exercise capacity after HSCT. Unfortunately, exercise capacity and peripheral muscle strength
are decreased in HSCT recipients in spite of doing regular and planned exercise during acute
process of HSCT. The average reduction in functional exercise capacity of recipients is 48 m.
As shown in the literature, limited number of study has used evaluation of maximal exercise
capacity with Modified-Incremental Shuttle Walk Test (ISWT) in HSCT patients and recipients.
On the other hand, it has been reported that ISWT is a reliable test and has no adverse event
or side effects for HSCT recipients in these studies, as well. Despite the fact that there is
no negative feedback related to using of this test in recipients, no study comprehensively
demonstrated influence of HSCT on maximal exercise capacity.
Impairments in pulmonary functions, respiratory muscle strength and maximal exercise capacity
have been demonstrated in limited number of studies. Moreover, there is no study compared
pulmonary functions, respiratory muscle strength and maximal exercise capacity between HSCT
recipients and healthy individuals. Therefore investigators aimed to compare aforementioned
outcomes between recipients and healthy individuals.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03918343 -
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
|
N/A | |
Not yet recruiting |
NCT05438823 -
Technology Supported Education Program Based on Human Care Theory
|
N/A | |
Not yet recruiting |
NCT02193399 -
Physiotherapy in Hematopoietic Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT00972101 -
Infusion of Expanded Cord Blood T Cells
|
Phase 1 | |
Completed |
NCT05421299 -
A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
|
||
Completed |
NCT04976933 -
Post-HSCT Medication Adherence mHealth App
|
||
Completed |
NCT04798495 -
Feasibility of a Rehabilitation Programme Targeted Patients Treated With Non-myeloablative Stem Cell Transplantation
|
N/A | |
Completed |
NCT00612274 -
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
|
Phase 0 | |
Active, not recruiting |
NCT04511130 -
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT05968963 -
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT02940093 -
Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers
|
N/A | |
Not yet recruiting |
NCT06077734 -
Muscle Stem Cell Quality in Atrophy
|
||
Terminated |
NCT00587990 -
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
|
Phase 1/Phase 2 | |
Terminated |
NCT00597441 -
Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation
|
Phase 1 | |
Active, not recruiting |
NCT03684083 -
Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients
|
||
Recruiting |
NCT00884338 -
Cognitive Function After Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00284713 -
Progenitor Cell Therapy in Dilative Cardiomyopathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00062543 -
Hepatic Artery Infusion of CD34+ Cells
|
Phase 1 | |
Completed |
NCT00781170 -
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT03364257 -
iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients
|